IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process

Catheterization and Cardiovascular Interventions

Volumn 75, Issue 6, 2010, Pages 914-918

  Sarno, Giovanna ^a   Onuma, Yoshinobu ^a   Garcia Garcia, Hector M ^b   Garg, Scot ^a   Regar, Evelyn ^a   Thuesen, Leif ^c   Dudek, Dariusz ^d   Veldhof, Susan ^e   Dorange, Cecile ^e   Ormiston, John A ^f   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CARDIALYSIS   (Netherlands)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d JAGIELLONIAN UNIVERSITY   (Poland)

^e ABBOTT VASCULAR   (United States)

^f AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

CATH diagnostic cardiac catheterization; IVUS intravascular ultrasound; PCI percutaneous coronary intervention

Indexed keywords

CALCIUM; EVEROLIMUS; POLYMER;

ADULT; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BIODEGRADABLE IMPLANT; BIOSORPTION; CALCIUM BLOOD LEVEL; CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; ECHOGENICITY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INTRAVASCULAR ULTRASOUND; MALE; MULTICENTER STUDY; NECROSIS; PALPOGRAPHY; PARAMETER; RADIOFREQUENCY; SILENT MYOCARDIAL ISCHEMIA; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS; VIRTUAL HISTOLOGY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HEART CATHETERIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NECROSIS; SIROLIMUS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 77951703674     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22332     Document Type: Article

References (13)

1. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel- Hebert K, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
2. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907. (Pubitemid 351384734)
3. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002;106:2200-2206. (Pubitemid 35222213)
4. Nair A, Margolis MP, Kuban BD, Vince G. Automated coronary plaque characterization with intravascular ultrasound backscatter: Ex-vivo validation. EuroIntervention 2007;3:113-120.
5. Garcia-Garcia HM, Gonzalo N, Pawar R, Kukreja N, Dudek D, Thuesen L, Ormiston JA, Regar E, Serruys PW. Assessment of the absorption process following bioabsorbable everolimus-eluting stent implantation: temporal changes in strain values and tissue composition using intravascular ultrasound radiofrequency data analysis. A substudy of the ABSORB clinical trial. Eurointervention 2009;4:443-448.
6. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-Von Kaeppler HA, Starling RC, Sørensen K, Hummel M, Lind JM, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847-858.
7. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006;81:1234-1248.
8. Vigano M, Tuzcu M, Benza R, Boissonnat P, Haverich A, Hill J, Laufer G, Love R, Parameshwar J, Pulpon LA, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007;26:584-592.
9. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998;30:2200-2203.
10. Matsumoto Y, Hof A, Baumlin Y, Hof RP. Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. Transplantation 2003;76:1166-1170.
11. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 2008;198:39-48.
12. Verheye S, Martinet W, Kockx MM, Knaapen MW, Salu K, Timmermans JP, Ellis JT, Kilpatrick DL, De Meyer GR. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 2007;49:706-715. (Pubitemid 46205042)
13. Martinet W, Verheye S, De Meyer GR. Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy. Autophagy 2007;3:241-244. (Pubitemid 46752686)